Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication

被引：2

作者：

Ma, Yanlei ^{[1
]}

Qin, Huanlong ^{[1
]}

Zheng, Qi ^{[1
]}

Wang, Yu ^{[1
]}

Wang, Zhiguo ^{[1
]}

Yang, Zhe ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Peoples Hosp Affiliated 6, Dept Surg, Shanghai 200233, Peoples R China

来源：

MEDICAL ONCOLOGY | 2010年 / 27卷 / 04期

关键词：

Neoadjuvant chemotherapy; Nonresectable advanced gastric cancer; Docetaxel; Cisplatin; Fluorouracil; Leucovorin; PHASE-II; PLUS FLUOROURACIL; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; D2; GASTRECTOMY; CARCINOMA; ADENOCARCINOMA; SURVIVAL; STRATEGIES; ETOPOSIDE;

D O I：

10.1007/s12032-009-9340-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to evaluate the efficacy and toxicity of docetaxel (TAX), cisplatin (CDDP), and fluorouracil (5-FU) plus leucovorin (CF) as the neoadjuvant chemotherapy (NACT) regimens in the treatment of nonresectable advanced gastric cancer. Twelve patients with nonresectable advanced gastric cancer were treated with NACT regimens consisted of docetaxel, cisplatin, fluorouracil, plus leucovorin before operation. Nine of the 12 patients were downstaged and 8 were radically operated after the end of the NACT. The overall response rate was 75% with 8.3% complete response and 66.7% partial response, and the ascites disappeared in 63.6%. The most common toxicities were bone marrow suppression, nausea, vomiting, alopecia, and heptoses. The toxicities were recoverable after symptomatic treatment. The results confirmed that the combination of docetaxel, cisplatin, fluorouracil plus leucovorin (CF) is a very effective and well-tolerated regimen as NACT for the patients with nonresectable advanced gastric cancer.

引用

页码：1089 / 1095

页数：7

共 50 条

[21] Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer [J].

Quintero-Aldana, G. ;

Jorge, M. ;

Grande, C. ;

Salgado, M. ;

Gallardo, E. ;

Varela, S. ;

Lopez, C. ;

Villanueva, M. J. ;

Fernandez, A. ;

Alvarez, E. ;

Gonzalez, P. ;

Castellanos, J. ;

Casal, J. ;

Lopez, R. ;

Campos Balea, B. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) :731-737

[22] Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer [J].

Kinro Sasaki ;

Shinichi Onodera ;

Kichiro Otsuka ;

Hitoshi Satomura ;

Eigo Kurayama ;

Tsukasa Kubo ;

Masakazu Takahashi ;

Jun Ito ;

Masanobu Nakajima ;

Satoru Yamaguchi ;

Kazuhito Miyachi ;

Hiroyuki Kato .

Medical Oncology, 2017, 34

[23] Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer [J].

Popov, I. ;

Radosevic-Jelic, L. ;

Jezdic, S. ;

Milovic, M. ;

Borojevic, N. ;

Stojanovic, S. ;

Stankovic, V. ;

Josifovski, T. ;

Kezic, I. .

JOURNAL OF BUON, 2008, 13 (04) :505-511

[24] Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer [J].

Emi, Manabu ;

Hihara, Jun ;

Hamai, Yoichi ;

Aoki, Yoshiro ;

Okada, Morihito ;

Kenjo, Masahiro ;

Murakami, Yuji .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) :1499-1505

[25] Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma [J].

Ming gao Guo ;

Qi Zheng ;

Jian zhong Di ;

Zhe Yang .

World Journal of Surgical Oncology, 12

[26] Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study [J].

Yu, Deguo ;

Wang, Zhenfeng ;

He, Tingbang ;

Yang, Lijun .

FRONTIERS IN SURGERY, 2022, 9

[27] Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer [J].

Maeda, Osamu ;

Furune, Satoshi ;

Kanda, Mitsuro ;

Miyata, Kazushi ;

Shimizu, Dai ;

Sugita, Shizuki ;

Nishida, Kazuki ;

Ando, Masahiko ;

Kodera, Yasuhiro ;

Ando, Yuichi .

CANCER MEDICINE, 2024, 13 (02)

[28] Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus [J].

Ojima, Toshiyasu ;

Nakamori, Mikihito ;

Nakamura, Masaki ;

Katsuda, Masahiro ;

Hayata, Keiji ;

Kato, Tomoya ;

Kitadani, Junya ;

Tabata, Hirotaka ;

Takeuchi, Akihiro ;

Iwahashi, Makoto ;

Yamaue, Hiroki .

ANTICANCER RESEARCH, 2016, 36 (02) :829-834

[29] Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil [J].

Mohri, Junichi ;

Katada, Chikatoshi ;

Ueda, Marie ;

Sugawara, Mitsuhiro ;

Yamashita, Keishi ;

Moriya, Hiromitsu ;

Komori, Shouko ;

Hayakawa, Kazushige ;

Koizumi, Wasaburo ;

Atsuda, Koichiro .

JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2018, 6 (01) :32-37

[30] A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer [J].

Li, Maoquan ;

Zhang, Jiaxing ;

Wang, Daoyuan ;

Zhong, Baoliang ;

Tucker, Steven ;

Lu, Chenhui ;

Cheng, Jie ;

Ca, Chuanwu ;

Xu, Jiahua ;

Xu, Jichong ;

Pan, Hui .

ANTI-CANCER DRUGS, 2009, 20 (10) :941-945

← 1 2 3 4 5 →